Travis Dalton
Analyst · Richard Close with Canaccord Genuity
Good morning. Thank you for joining us. We're pleased to announce another strong quarter for Claritev and continued progress on our turnaround journey. You are what your record says you are, and our results demonstrate that our strategy is working, our execution is strengthening, growth is returning, and we are building forward momentum across the business. The hard work and discipline over the last 2 years of laying the foundation of clarity, alignment, focus resulted in the turn last year, which has positioned us to take advantage of the opportunities in front of us. At our Investor Day in March, we introduced 2026 as the year of the way up, which is a return to sustainable growth in our multiyear transformation. The first half of the year has demonstrated that our strategy of driving horizontal solutions in vertical markets is working. In addition to focusing on our core client solutions and attacking new markets, we're building leaders in a culture of growth at the company. I'm most proud of the way our people have embraced change and new opportunities to impact health care. We also have made thoughtful and smart investments in our technology platforms, data architecture and talent over the last 2 years. Our technology modernization positions us to quickly adapt and harness the power of new tools and technology like AI to bring more value to clients much faster. The organizations that have the knowledge and aligned structurally to unleash the potential of AI will be winners going forward. Our greatest asset is the knowledge and industry acumen we possess versus the competition. On today's call, I'll cover our strong second quarter results, the macro health care environment that demonstrates the challenges we are so good at tackling for consumers of health care, the continued progress and potential we see in AI. Let me begin with our Q2 performance, which exceeded our expectations on nearly every key metric. Revenue and adjusted EBITDA both came in above plan. We had another great bookings quarter, exceeding $70 (sic) [ 74 ] million ACV for the first half of 2026 and well on our way to achieve our $100 million full year stretch target. Just as important, we are seeing larger deal sizes, broader contribution from our entire sales team, improving win rates and a healthy and growing pipeline. Doug will give some color on the conversion cycle from bookings to revenue, but this quarter's business performance validates the foundation against the multiyear financial goals that we outlined at our Investor Day. I do want to highlight one area that we stressed on our first quarter earnings call, where we have ramped up our focus and brought in new leadership and that's the third-party administrator or TPA business. The TPA vertical represented our largest contributor to second quarter bookings with several 7-figure deals. Among them was Marpai, which selected our payment and revenue integrity solutions for both prepaid and postpaid claims. We also expanded adoption of our network and advanced code editing solutions across the TPA market. Equally important is the breadth of our momentum with wins spanning large national TPAs, regional mid-market organizations and technology-focused players. Our new segment leader, Dallas Scrip, has provided immediate energy to the business, and we expect this segment to contribute roughly 30% of our total new bookings this year, second only to our payer segment. We also see an expanded opportunity in Medicare Advantage. We recently signed a high 6-figure ACV deal in new logo in the quarter to build an MA network. While not a significant revenue driver for us today, we believe it represents a meaningful long-term growth opportunity as plans increasingly seek solutions that improve payment accuracy, optimize networks, identify high-cost trends and enhance provider performance. This is an example of the diversification strategy we set in motion over the past 2 years, and we're beginning to see it translate into a broader, more durable growth profile. Taken together, our bookings momentum and revenue growth reinforce our confidence in the long-term strategy, focus on our core solutions and faster innovation with our existing clients, expand aggressively across new vertical markets with those solutions, create new capabilities for launch that the cost reduction and transparency demand of the market. This strategy is starting to yield sustainable growth momentum that will allow us the financial flexibility to invest, drive down our debt leverage over time, improve operating leverage and unlock free cash flow to maximize long-term value. Next, I'd like to highlight several macro trends that continue in health care and make our mission of affordability and transparency so important. First, medical cost trends continue to rise with medical inflation running between 8% and 10% annually, well above overall economic growth. Health care spending is almost 20% of U.S. GDP, creating significant pressure on employers, the government and consumers. Claritev exists to help solve that problem, whether it's our network providing access to predictable care, transparency solutions bringing insights, PRI solutions tapping waste, or Claims intelligence driving cost savings. Simply put, we make health care more affordable for consumers. Second, self-funded plan enrollment remains stable and out-of-network claim volumes have remained in the mid-7% range over the last 5 years. Utilization is stable, but mix is shifting to higher cost areas such as emergency care, behavioral health and specialty facilities, creating a durable demand environment for our network, payment and revenue integrity and No Surprises Act solutions. And third, the regulatory complexity persists with NSA IDR changes and reduced federal funding for several programs. These changes and challenges can only be met by nimble, scaled technology-enabled companies like Claritev. Affordability and transparency remains central priorities for the federal government, aligning closely with our core capabilities and strategies. Let me highlight a key area where government intervention is most measurable. 2022 introduction of the No Surprises Act and the independent dispute resolution process. The recently finalized IDR rules increased the operational and compliance requirements for both payers and providers. As those requirements grow, our scale, technology and expertise become even more valuable. No company has demonstrated a greater ability to manage NSA claims at scale than Claritev. Our arbitration outcomes continue to outperform the industry by approximately 8 percentage points, and we're seeing existing clients consolidate more of their NSA workflow onto our platform. The same dynamics are driving demand across our Payment and Revenue Integrity portfolio. As health care organizations face increasing pressure to reduce costs, identify fraud, waste and abuse and improve payment accuracy, our solutions become increasingly strategic. We're proud that Everest Group recently recognized Claritev as a leader in payment integrity and wins like the Marpai engagement underscore the growing momentum we continue to see across this portfolio. Finally, let me turn to AI. We view artificial intelligence as an accelerator of both growth and operating leverage in an area where Claritev has built a meaningful competitive advantage. AI is only as valuable as the quality of the data behind it, the harness engineering engage, the workflows it improves and the trust users place in its recommendations. Those are areas where Claritev stands apart. Our multiyear digital transformation positioned us well before AI became today's headline. We have organized data, modern cloud-based workflow and deep domain expertise that allows us to deploy AI responsibly and at scale. Today, we're already using AI across numerous models and production use cases to improve efficiency, accelerate decision-making and deliver better outcomes for our clients. We have AI initiatives across all solutions and business functions, but I'll focus today on a few IDR examples where the need and the impact can be seen immediately. If you listen to recent health care earnings calls or read any of the current articles related to NSA, you know that the system is being overwhelmed with volume that drives unnecessary administrative cost and delay. Payers on behalf of employers often have only a narrow window to validate claims, identify missing information and screen out ineligible submissions. Our analysis indicates that nearly half of all IDR submissions are ineligible, highlighting a significant opportunity to use AI to improve efficiency and accelerate our clients' ability to respond quickly. This is where Claritev's combination of scale, data and AI makes a meaningful difference. Over the past 6 months, we've launched AI-powered capabilities that automate provider data validation and ineligibility assessments, improving both speed and accuracy. We're also automating case creation for resubmission and enhancing predictive models that optimize pre arbitration strategy. Together, these types of innovations reduce operating costs, improve outcomes and resolve disputes earlier in the process, which is good for both parties. Finally, we operate in a highly competitive environment with large and growing challenges facing our clients. The need for more health care affordability and transparency has never been greater. Our strategy is delivering results, and we have the people, technology, data and client relationships to capitalize on the opportunities to deliver right now and in the future. With that, let me turn the call over to Doug.